Cargando…

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal vaccination, especially through oral or intranasal administration routes, is highly desired for infectious diseases. Meanwhile, protein-based antigens provide a safer alternative to the whole pathogen or DNA ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shujing, Liu, Huiqin, Zhang, Xinyi, Qian, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491048/ https://www.ncbi.nlm.nih.gov/pubmed/25944045 http://dx.doi.org/10.1007/s13238-015-0164-2

Ejemplares similares

COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
por: Dhama, Kuldeep, et al.
Publicado: (2022)

Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges
por: Kar, Sanchita, et al.
Publicado: (2022)

Advantages of Intranasal Vaccination and Considerations on Device Selection
por: Birkhoff, M., et al.
Publicado: (2009)

Strategies for intranasal delivery of vaccines
por: Zaman, Mehfuz, et al.
Publicado: (2012)

Comparative onset of immunity of oral and intranasal vaccines against challenge with Bordetella bronchiseptica
por: Scott-Garrard, Maya M, et al.
Publicado: (2018)

Does orally dissolving formulation of clobazam provide clinical advantage over it's standard formulation
por: Patil, Anant Dhondopant
Publicado: (2016)

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan
por: Popescu, Roxana, et al.
Publicado: (2020)

Silicone Oil-Based Nanoadjuvants as Candidates for a New Formulation of Intranasal Vaccines
por: Razim, Agnieszka, et al.
Publicado: (2021)

Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
por: Saluja, Vinay, et al.
Publicado: (2010)

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy
por: Abhyankar, Mayuresh M., et al.
Publicado: (2021)

Intranasal Immunization with an Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery Formulation Protects against a Respiratory Pathogen Challenge
por: Patel, Girishchandra B., et al.
Publicado: (2010)

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators
por: Tandrup Schmidt, Signe, et al.
Publicado: (2016)

Design and Efficacy of Nanogels Formulations for Intranasal Administration
por: Aderibigbe, Blessing A., et al.
Publicado: (2018)

Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge
por: Zuo, Zonghui, et al.
Publicado: (2021)

Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges
por: Pozharov, Vitaly P., et al.
Publicado: (2023)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder
por: Ball, Jordan P., et al.
Publicado: (2017)

Protective Enterotoxigenic Escherichia coli Antigens in a Murine Intranasal Challenge Model
por: Kumar, Amit, et al.
Publicado: (2015)

A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine
por: Scadding, Glenis Kathleen
Publicado: (2022)

Formulation, High Throughput In Vitro Screening and In Vivo Functional Characterization of Nanoemulsion-Based Intranasal Vaccine Adjuvants
por: Wong, Pamela T., et al.
Publicado: (2015)

Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges
por: Choi, Hojun, et al.
Publicado: (2022)

An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
por: Rahman, Md. Motiar, et al.
Publicado: (2021)

Formulation technologies for oral vaccines
por: New, R. R. C.
Publicado: (2019)

Advantages of an Oral Vaccine to Control the COVID-19 Pandemic
por: Baker, Phillip J.
Publicado: (2022)

Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion
por: Patel, Mikesh B., et al.
Publicado: (2012)

Intranasal Vaccination with Mannosylated Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the Lungs of Mice and Improves Protection against Pulmonary Mycobacterial Challenge
por: Wu, Manli, et al.
Publicado: (2017)

Optimization of formulation for enhanced intranasal delivery of insulin with translationally controlled tumor protein-derived protein transduction domain
por: Bae, Hae-Duck, et al.
Publicado: (2019)

The Effect of Plant Tissue and Vaccine Formulation on the Oral Immunogenicity of a Model Plant-Made Antigen in Sheep
por: Pelosi, Assunta, et al.
Publicado: (2012)

Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants
por: Han, Sumin, et al.
Publicado: (2023)

Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil
por: Al Asmari, Abdulrahman K, et al.
Publicado: (2016)

Preventing airborne infection with an intranasal cellulose powder formulation (Nasaleze Travel®)
por: Hiltunen, Raimo, et al.
Publicado: (2007)

Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)
por: Wang, Dan, et al.
Publicado: (2021)

Administration of paediatric intranasal sedation: Need for appropriate formulation & equipment for dispensation
por: Parida, Satyen, et al.
Publicado: (2023)

Gamified Neurorehabilitation Strategies for Post-stroke Motor Recovery: Challenges and Advantages
por: Tosto-Mancuso, Jenna, et al.
Publicado: (2022)

Vascular organoids: unveiling advantages, applications, challenges, and disease modelling strategies
por: Naderi-Meshkin, Hojjat, et al.
Publicado: (2023)

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
por: Hu, Mary C., et al.
Publicado: (2007)

Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies
por: Barnard, Dale, et al.
Publicado: (2007)

MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice
por: Kim, Hye-Jung, et al.
Publicado: (2020)

Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
por: Hill-Batorski, Lindsay, et al.
Publicado: (2023)

Quality by Design Based Formulation Study of Meloxicam-Loaded Polymeric Micelles for Intranasal Administration
por: Sipos, Bence, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a23lvdrquj24cnohn87h55udpu